USA Equities Corp. Reports First Quarter 2021 Financial Results and Announces Upcoming Presentation at the University of Miami

    Substantial Sequential Increase in Revenue and Gross Margin
    Growth in Customer Base and Revenue Per Customer Compared to Q4 2020
    Company Expects Sequential Increase in Gross Margin in Q2 2021
    USAQ
Medical Advisory Board Presenting at the University of Miami Miller School of Medicine CME Workshop on June 26, 2021

West Palm Beach, FL, May 18, 2021 (GLOBE NEWSWIRE) — USA Equities Corp. (OTCQB: USAQ), a company focused on value-based healthcare solutions and physician-directed digital medicine, today announces its first-quarter financial results for the period ended March 31, 2021, reporting strong sequential growth and setting expectations for the second quarter.

“We made excellent progress executing on our financial and strategic priorities in the first quarter of 2021,” stated USAQ Chief Executive Officer Troy Grogan. “On a sequential basis, our revenue more than doubled to approximately $304,000, while gross margin improved 370 basis points to 43.9%. This growth is due to increased sales of allergy diagnostic kits and immunotherapy treatments as well as expansion of our customer base We also saw continued momentum in April, and currently expect an increase in revenue and gross margin in the second quarter of 2021.”

Business Highlights

“From a strategic perspective, several significant accomplishments in the quarter further strengthened our business model and management team. We amended our distribution agreement with MedScience Research Group regarding AllergiEnd®’s allergy diagnostic and Allergen immunotherapy products; as a result, our distribution fee payment to MedScience was reduced by 20%, which will substantially increase our gross margin beginning with the second quarter of 2021. We also announced the appointment of Michael Mangus to our advisory and physician network development team. Mike is a highly experienced and respected executive in the medical device and technology industry, and I believe he will be a valuable addition as we further commercialize our digital medicine and virtual care technologies,” stated Grogan.

“Additionally, increased visibility of USAQ in the industry through participation in continuing medical education programs focused on our core markets is contributing to our success. As the number of potential physician clients for our products and services contacted by us expands, so does the level of positive customer feedback we receive. For example, in March, five of our medical advisory board members presented at the inaugural University of Miami Allergy Diagnostics and Allergen Immunotherapy Virtual CME event. Our team will also participate in a similar workshop at the University of Miami’s Miller School of Medicine on June 26, 2021. Through these events, we are able to further educate medical practitioners regarding our solutions to enhance patient quality of life through physician-directed digital medicine as well as driving revenue opportunities for physicians in their own practices.

“In sum, we believe we are in the early stages of building a robust medical device technology and software platform supported by significant recurring revenue, large and growing addressable markets, and a highly energized management and advisory team. Our targeted solutions enable primary care physicians to provide preventive solutions with value-based digital tools to evaluate and treat chronic disease through reimbursable procedures. Over time, we expect to launch additional products and services which will further grow our revenue per customer and client base while leveraging our cost structure,” concluded Grogan.

First Quarter 2021 Financial Results

*USAQ began selling AllergiEnd® Allergy Diagnostics and Allergen Immunotherapy treatments in the fourth quarter of 2020.

    Revenues for the three months ended March 31, 2021, were $304,336, an increase over revenues of $124,532 reported in the fourth quarter of 2020 due to growth in both Allergy Diagnostic Kits and Immunotherapy Treatment sales, which the Company initiated in the fourth quarter of 2020.
    First-quarter 2021 sales of Allergy Diagnostic Kits were $187,040 compared to fourth-quarter 2020 sales of $77,210; first-quarter 2021 sales of Immunotherapy Treatments were $107,853 compared to sales of $43,586 in the prior quarter.
    The Company generated gross profit of $133,579, or a gross margin of approximately 43.9%, in first quarter 2021 compared to gross profit of $50,093 or a gross margin of 40.2% in fourth quarter 2020. The increase was primarily attributable to the larger base of sales as well as customer and product mix.
    Sales and marketing expenses of $111,688 in first quarter 2021 compared to $66,120 for fourth quarter 2020, as we hired additional personnel and further expanded the launch of our products.
    General and administrative expenses of $70,127 in first quarter 2021 compared to $94,343 in fourth quarter 2020.

About USA Equities Corp.

USA Equities Corp. (OTCQB: USAQ) is focused on providing value-based healthcare solutions, clinical informatics and algorithmic personalized medicine including digital therapeutics, behavior-based remote patient monitoring, chronic care and preventive medicine. The Company’s products are intended to allow general practice physicians to increase revenues by cost effectively diagnosing and treating chronic diseases that are generally referred to specialists. The Company’s products and information service portfolio are directed toward prevention, early detection, management and reversal of allergies, cardio-metabolic and other chronic diseases. Our principal objectives are to develop proprietary software tools, point of care devices and approaches, providing more granular, timely and specific clinical decision-making information for practicing physicians and other health care providers to address today’s allergy prone, obese, diabetic and cardiovascular disease population.

For additional information, visit the Company’s website at www.USAQCorp.com

Forward-Looking Statements

Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products and potential future results and acquisitions, are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘expects’, or ‘intends’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products and the acceptance of these products, the inherent discrepancy in actual results from estimates, projections and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Investor & Media Contact:  
   
Olivia Giamanco  
USA Equities Corp  
(929) 379-6503  
[email protected]  



Verano Holdings Announces First Quarter 2021 Results

  • First quarter 2021 revenue of $143 million, growth of approximately 117% year-over-year
  • Gross profit margin of over 62% for first quarter 2021
  • First quarter 2021 net income of $126 million, including the impact of biological assets, and $8 million excluding the impact of biological assets
  • First quarter 2021 adjusted EBITDA of $75 million, an industry-leading 52% margin

CHICAGO, May 18, 2021 (GLOBE NEWSWIRE) — Verano Holdings Corp. (CSE:VRNO) (OTCQX: VRNOF) (“Verano” or “the Company”), a leading multi-state cannabis company, today announced its financial results for the first quarter ended March 31, 2021. The financial information below is reported on a pro forma consolidated basis accounting for the AltMed acquisition as if completed on January 1, 2021, and all currency is in U.S. dollars, unless otherwise noted.

First Quarter
202
1
Financial
Highlights

  • First quarter 2021 revenues increased 117% from the first quarter 2020 to $143 million.
  • First quarter gross profit, on an unadjusted basis and not including the impact of biological assets, was $89 million or 62% of revenue, compared to $50 million in the first quarter 2020.
  • First quarter 2021 SG&A expense was $29 million or 20% of revenue, compared to $14 million or 21% of revenue in the first quarter 2020.
  • Net income in first quarter 2021, including the impact of biological assets, was $126 million compared to $72 million in the first quarter 2020. Excluding the impact of biological assets, net income was $8 million in the first quarter 2021.
  • First quarter 2021 EBITDA1 on an unadjusted basis was $60 million or 42% of revenues, and Adjusted EBITDA1 was $75 million or 52% of revenues.
  • Cash flow from operations for first quarter 2021 was $42 million, and free cash flow1 was $4 million.

Recent
Operational Highlights

  • Verano completed the acquisitions of Territory, Emerald, and Local Joint, all in Arizona, giving the Company the third largest retail footprint in the state with six active storefronts plus two cultivation facilities.
  • The Company was upgraded to the OTCQX Best Market, which is expected to increase visibility and improve liquidity for investors, and marks another step toward maximizing long-term shareholder value.
  • Verano completed a private placement raising gross proceeds of approximately C$100 million, with warrants issued in the offering being priced at C$28.50 for one Class A subordinate voting share of the Company.
  • In first quarter 2021, the company brought four new dispensaries online in as many states.
  • In April, the Company opened its second of three planned Zen Leaf dispensaries in New Jersey, where the expansion of its 120,000 sq. ft. cultivation facility is underway in anticipation of the onset of adult use sales in the state.
  • The Company completed acquisitions of TerraVida and The Healing Center, adding six dispensaries in Pennsylvania – three in the Philadelphia metroplex and three in the Pittsburgh metroplex – and also acquired a permit for the development of three additional dispensaries in the state.
  • In May, the Company upsized its existing credit facility by $100 million, with an industry-leading 9.75% interest rate on a non-dilutive basis.
  • Verano announced it has entered into agreements for the acquisitions of Agri-Kind and Agronomed Biologics in Pennsylvania, which are expected to add an active and completely built-out, state-of-the-art 62,000 sq. ft. indoor grow facility, in addition to further developing the Company’s vertically integrated footprint with a permit for six new dispensaries and a second cultivation and production facility.

(1) See Non-IFRS Financial Measures below.

Management Commentary

“Our strong first quarter performance was foundational in nature and sets the tone for what we expect to be a transformational year. We anticipate considerable quarter-over-quarter growth in 2021 as we begin to realize the impact of accretive acquistions we’ve made over the last few months, in addition to broad expansion of cultivation capacity and organic retail growth,” said George Archos, Verano CEO and Founder. “I am very pleased with our accomplishments to-date, particularly how well we’ve executed on our growth strategy. We’ve expanded our retail footprint and production capacity in core markets where we’ve identified substantial near- and long-term upside. Our management team has risen to every occasion, effectively guiding integrations across our markets to maximize a growing talent pool, while unearthing operational efficiencies along the way. We believe we are poised to deliver on our stated objectives, to maintain an industry-leading margin profile through considerable expansion, and we expect to deliver added shareholder value into the foreseeable future.”

Balance Sheet and Liquidity

As of March 31, 2021, the Company’s current assets on a pro forma consolidated basis were $549 million, including cash and cash equivalents of $112 million. The Company had working capital of $329 million and total debt, not including lease liabilities and net of issuance costs, of $34 million.

Total shares on an as-converted basis are 303,609,405 as of May 17, 2021.

Additional Information

The financial information reported in this news release is based on the unaudited financial statements of Verano Holdings Corp. and the related management discussion and analysis (“MD&A”) for the three months ended March 31, 2021, both of which are available under the Company’s profile on SEDAR at www.SEDAR.com. All financial information contained in this news release is qualified in its entirety with reference to such financial statements and MD&A.

Non-IFRS Financial Measures

Verano refers to certain non-IFRS measures to evaluate the performance of the Company. The terms “EBITDA”, “Adjusted EBITDA” and “Free Cash Flow” do not have any standardized meaning prescribed within International Financial Reporting Standards (“IFRS”) and therefore may not be comparable to similar measures presented by other companies. Such measures should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. EBITDA is calculated as net earnings from operations before interest expense, tax expense, depreciation, and amortization. Adjusted EBITDA is calculated as EBITDA adjusted for one-time expenses related to other expenses, gain from investment in associates and acquisition related costs. Free Cash Flow is calculated as cash flow from operations minus capital expenditures. Reconciliations of the non-IFRS financial measures used in this news release to the most comparable IFRS financial numbers are included tables at the end of this news release.

Management believes that these non-IFRS financial measures provide useful information as a supplement to reported IFRS financial information. Management reviews these non-IFRS financial measures on a regular basis and uses them to evaluate and manage the performance of the Company’s operations. These measures should be evaluated only in conjunction with the Company’s comparable IFRS financial measures.

Conference Call
and Webcast

A conference call and audio webcast with analysts and investors will be held today at 8:30 a.m. Eastern Time/7:30 a.m. Central Time, to discuss Verano’s first quarter 2021 financial results and answer questions.

  • Investors and participants can register for the call by visiting this page. After registering, instructions will be shared on how to join the call for those who wish to dial in.
  • Live and archived webcast will be available on the Events and Presentations page of Verano’s investor relations website at investors.verano.com.

About Verano

Verano Holdings Corp. is a leading, vertically-integrated, multi-state cannabis operator in the U.S., devoted to the ongoing improvement of communal wellness by providing responsible access to regulated cannabis products. With a mission to address vital health and wellness needs, Verano produces a comprehensive suite of premium, innovative cannabis products sold under its trusted portfolio of consumer brands: Verano, Avexia, Encore, and MÜV. The Company’s portfolio encompasses 14 U.S. States, with active operations in 11, which includes nine production facilities comprising approximately 770,000 square feet of cultivation. Verano designs, builds, and operates dispensaries under retail brands Zen Leaf and MÜV, delivering a superior cannabis shopping experience in both medical and adult-use markets. Learn more at www.verano.com

Forward Looking Statements

This news release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. Forward-looking information and forward-looking statements may include, but are not limited to statements or information with respect to the Company’s position in the marketplace, the proposed completion or buildout of Company facilities, the Company’s cultivation capacity, the completion of pending acquisitions, the accretive nature of acquisitions, the fortification of the Company’s presence in core markets, the possibility of material organic expansion, delivery of shareholder value and the ability to maintain industry-leading margins and add depth to leadership.

Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein, including, without limitation, the risk factors discussed in the Company’s filings including our financial statements and MD&A for the fiscal year ending December 31, 2020 and our financial statements and MD&A for the three months ended March 31, 2021 on SEDAR at www.sedar.com

The forward-looking information and forward-looking statements contained in this new release are made as of the date of this news release, and the Company does not undertake to update any forward-looking information or forward-looking statements that are contained or referenced herein, except as may be required in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice regarding forward-looking information and statements.

Verano Holdings Corporation Pro Forma

Unaudited Financial Information

(All amounts expressed in thousands of U.S. Dollars)

Unaudited Consolidated Statements of Operations

For the Three Months Ended March 31, 2021 and 2020

    For the Three Months Ended  
    March 31  
($ in thousands)   2021     2020  
    (Unaudited)     (Unaudited)  
Revenue   $ 143,297     $ 66,059  
Cost of Sales     (54,605 )     (15,618 )
Gross Profit Before Fair Value Adjustments of Biological Assets     88,693       50,441  
Gross Profit % Before Changes In Fair Value of Biological Assets     61.9 %     76.4 %
                 
Net Effect of Changes in Fair Value of Biological Assets     117,408       54,024  
Gross Profit     206,100       104,465  
                 
Expenses:                
Selling, General and Administrative1     29,206       14,081  
Depreciation and Amortization     2,957       2,821  
Total Expenses     32,163       16,902  
                 
Income (Loss) from Investments in Associates     803       4,528  
                 
Income (Loss) from Operations     174,740       92,091  
                 
Total Other Income (Expense), Net     (3,135 )     (4,140 )
Gain (Loss) Before Income Taxes     171,605       87,951  
Income Tax Expense     45,327       16,108  
Net Income Attributable To Non-Controlling Interest     706       168  
Net Income    $ 125,573     $ 71,676  

Verano Holdings Corporation Pro Forma

Unaudited Summarized Consolidated Statements of Financial Position

As of March 31, 2021 and 2020 

    For the Three Months Ended  
    March 31  
($ in thousands)   2021 1     2020  
    (Unaudited)     (Unaudited)  
Cash and Cash Equivalents   $ 111,637     $ 19,834  
Other Current Assets     437,083       142,418  
Property and Equipment, Net     247,570       148,932  
Intangible Assets, Net     722,917       19,880  
Goodwill     222,525       5,597  
Other Long-Term Assets     37,600       65,133  
Total Assets   $ 1,779,332     $ 401,795  
                 
Total Current Liabilities   $ 220,043     $ 88,284  
Total Long-Term Liabilities     295,083       38,315  
Total Shareholders’ Equity     1,264,205       275,197  
Total Liabilities and Shareholders’ Equity   $ 1,779,332     $ 401,795  

1 2021 consolidated statement reported on IFRS-basis

 Verano Holdings Corporation Pro Forma

Unaudited Reconciliation of Net Income to Adjusted EBITDA and Non-IFRS

For the Three Months Ended March 31, 2021 and 2020

    For the Three Months Ended  
($ in thousands)   March 31,  
    2021     2020  
    (Unaudited)     (Unaudited)  
Net Income1   $ 125,573     $ 71,676  
Depreciation and Amortization     5,110       2,821  
Interest Expense, Net     1,633       380  
Income Tax Expense     45,327       16,108  
Earnings (Loss) Before Interest, Taxes, Depreciation
and Amortization (EBITDA) (Non-IFRS)
  $ 177,644     $ 90,984  
                 
Other expense (income), net     1,268       3,760  
Acquisition, transaction, and other non-operating costs     13,543       651  
Adjusted EBITDA (Non-IFRS)   $ 192,454     $ 95,395  
                 
Net Impact of Fair Value of Biological Assets     (117,408 )     (54,024 )
Adjusted EBITDA (non-IFRS), Net of Impact of Biological Assets   $ 75,047     $ 41,372  

1 Net Income excludes amounts attributable to non-controlling interest. 

Contacts:

Investors

Verano Holdings
Aaron Miles
Head of Investor Relations
[email protected]

Media

Verano Holdings
David Spreckman
VP, Marketing & Communications
[email protected]



Celona Introduces New Architecture For the Edgeless Enterprise

New approach brings vital network services closer to users and applications to help companies achieve the highest levels of performance wherever new digital business initiatives demand

CUPERTINO, Calif., May 18, 2021 (GLOBE NEWSWIRE) — Celona, one of the leading innovators of private 5G solutions, today debuted its Edgeless Enterprise architecture that enables uniform orchestration of vital network connectivity, edge computing, and security services. As organizations embrace this unique approach across their campus and branch locations, they get one step closer to moving at the speed of the new generation of enterprise applications.

Based on the transformative principles of 5G technology, Celona’s Edgeless Enterprise is an architectural approach that converges network services, enterprise applications, cybersecurity tools, and WAN optimization on cloud-native edge computing platforms that can be deployed anywhere. This innovative new approach enables myriad benefits, including:

  • Gaining and maintaining a competitive edge by rolling out new automation and digital transformation services faster than ever before,
  • Removing friction by streamlining network and security service provisioning,
  • Reducing operational cost inefficiencies by leveraging AIOps with a cloud-native network operating system, and
  • Decreasing security exposure by unifying the policy framework independent of network access and compute location options.

“In today’s fast-changing business environment, network services need to be in lockstep with enterprise applications,” said Rajeev Shah, co-Founder and CEO of Celona. “Celona’s Edgeless Enterprise architecture is the first comprehensive approach that uses the true value of emerging 5G technology to speed the convergence of network services and applications wherever they need to reside.”

As users and things connect over a variety of different networks, the application layer is increasingly dispersed over a broad continuum of potential compute locations. Today’s conventional enterprise network and security architectures were not designed for such a dynamic structure. Choices including private and public clouds, edge computing architectures, and multi-tenant edge clouds create complex environments for IT to manage. This complexity has often resulted in a patchwork of solutions that are as different as the various combinations of network access and compute locations themselves. This overly complex infrastructure foundation is unable to keep pace with the rapid change driven by digital transformation efforts within the enterprise.

ENTER THE EDGELESS ENTERPRISE

Designed to deliver unprecedented operational agility and efficiency within a scalable framework, the Edgeless Enterprise architecture relies on a cloud-native network operating system. It provides an all-in-one network service overlay that offers policy-based routing, QoS, and security segmentation functions. It also takes advantage of granular 5G network slicing principles to guarantee key service levels and a consistent application delivery experience.

Celona’s unique approach supports the convergence of radio access network (RAN), application, and network service traffic, automatically shifting the delivery route of services based on performance, policy requirements, and network paths’ real-time health.

“Now organizations can begin moving away from the conventional network service framework towards a more agile, Microsoft Azure managed edge computing environment that brings essential network service functions closer to the real-time applications,” said Tad Brockway, Corporate Vice President at Microsoft Azure for Operators. “With our collaboration with Celona, private mobile network services are effectively deployed next to business applications running on the same Azure edge platform for greater levels of operational efficiency and the ability to simultaneously automate the deployment of essential application and network resources with consistent cloud management.”

With Celona’s Edgeless Enterprise architecture, network services are effectively deployed as microservices next to business applications running on the same platform for greater levels of operational efficiency and the ability to simultaneously automate the allocation of essential application and network resources as demands change.

As the critical applications in the enterprise are deployed across a variety of on-premises, private, and public cloud options depending on their compute requirements, the traditional definition of the “Edge” no longer applies. With Celona’s Edgeless Enterprise architecture, the physical location or locations of the enterprise edge is now wherever it makes the most sense from a traffic optimization perspective. Determining the ideal deployment location of the network services depends on where latency/jitter-sensitive applications reside, how the application traffic should be routed for optimal performance and how security services should be enforced.

The use of SDN (Software Defined Networking) principles within the Celona platform allows for a separation of the 5G network control plane from the data plane. While the control plane manages higher-level functions such as mobility, authentication, and network resource management, the data plane performs traffic encryption, app-specific service level guarantees, enterprise network integration, and policy-based routing for each individual application slice.

Data plane tasks required to create QoS, routing, and security policy can be manually managed by IT staff or automated through AI to identify application traffic and apply network/security policy based on derived business intent. With Celona’s patent-pending MicroSlicing™ technology, application traffic can be automatically identified, secured, and routed per slice and enterprise policy.

Interested parties can find out more by reviewing Celona’s whitepaper hosted at https://celona.io/edgeless-whitepaper and joining Celona during its upcoming webinar “Triple Header: Private 5G, Edge Compute and IoT” this May 26, 2021, at 9 am Pacific time by registering at this link – https://www.celona.io/resources/triple-header-private-5g-edge-compute-and-iot.

ABOUT CELONA

Celona, the enterprise 5G company, is focused on accelerating the adoption of business-critical apps on enterprise wireless and helping organizations implement a new generation of digital business initiatives. Taking advantage of dynamic spectrum sharing options such as CBRS in the United States, Celona’s Edgeless Enterprise architecture is designed to automate the adoption of 5G cellular wireless technology by enterprise organizations and their technology partners. For more information, please visit celona.io and follow Celona on Twitter @celonaio.

MEDIA CONTACT

Jay Nichols
Nichols Communications
[email protected]
+1 (408)772-1551



Resgreen Group International (OTCPink: RGGI) Delivers Wanda SD to Atlantic Precision Products of Michigan

Clinton Township, Michigan, May 18, 2021 (GLOBE NEWSWIRE) — Resgreen Group International (OTCPink: RGGI), a leading mobile robot company, announces the delivery of Wanda SD to Atlantic Precision Products, an injection molding company located in Shelby Township, Michigan.

“In further efforts to maintain a safe workspace for our employees, Atlantic Precision Products has taken additional steps by implementing Wanda SD’s highly effective sanitizing effects,” stated Rodger Cherry, COO of Atlantic Precision Products.

Wanda SD uses Ultraviolet-C (UVC) light, as well as Ozone, to destroy more than 99 % of dangerous bacteria and viruses on floors, walls, tables, equipment, and other surfaces. The mobile vehicle’s non-toxic, residue-free process gives it an advantage over other deep cleaning methods.

With the use of smartphones or tablets, Wanda SD is able to be safely guided without the risk of human exposure to UVC light. Safety sensors allow the mobile vehicle to detect objects in its path and human presence within the vicinity. Upon completion of sanitization the vehicle’s software broadcasts a message indicating the task is finished.

Parsh Patel, CEO of Resgreen Group International shared, “We are pleased that APP has chosen Wanda SD as an additional component in their continued efforts to keep their employees and work spaces safe from dangerous pathogens. All of us at RGGI are delighted to be a part of aiding businesses in operating with greater peace of mind.” 

About Resgreen Group International, Inc. (RGGI)

RGGI is a leading developer of Artificial Intelligence Robotics (AIRs), Autonomous Mobile Robots (AMRs), and Automatic Guided Vehicles (AGVs). RGGI’s highly skilled engineers have years of experience in the material handling and robotics industries, which has led to significant intellectual property for the company.

RGGI also provides consulting services including backend operational oversight, material handling assessment, work-flow analysis, and steady state yield management using artificial intelligence, technology, and management systems. For more information visit http://resgreenint.com.



Sarah Carlson
[email protected]
248.755.7680

or

ResGreen Group International, Inc.
Parsh Patel, President and CEO
[email protected]

Axogen, Inc. to present at the Jefferies Virtual Healthcare Conference and the JMP Securities Life Sciences Conference

ALACHUA, Fla. and TAMPA, Fla., May 18, 2021 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president and Peter J. Mariani, executive vice president and CFO will present at two upcoming investor conferences.

Zaderej and Mariani will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 11:30 a.m. ET.

They will present at the JMP Securities Life Sciences Conference on Wednesday, June 16, 2021 at 12:30 p.m. ET.

The presentations will be webcast live and can be accessed through the Investors page at www.axogeninc.com. For those not available to listen to the live broadcast, a replay will be archived for 90 days and available through the Investors page on www.axogeninc.com.

About Axogen

Axogen (AXGN) is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven, and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.

Axogen’s platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance® Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard Nerve Connector®, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerve Protector®, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard Nerve Cap®, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive® Soft Tissue Membrane, a processed human umbilical cord intended for surgical use as a resorbable soft tissue barrier. The Axogen portfolio of products is available in the United States, Canada, Germany, United Kingdom, Spain, South Korea, and several other countries.

Contact:
Axogen, Inc.
Peter Mariani, Executive Vice President and Chief Financial Officer
[email protected]



Walmart U.S. Q1 comp sales grew 6.0%; 16.0% on a two-year stack

Walmart U.S. Q1 comp sales grew 6.0%; 16.0% on a two-year stack

Q1 FY22 GAAP EPS of $0.97; Adjusted EPS of $1.69

Walmart U.S. eCommerce sales increased 37%

Walmart U.S. gains market share in grocery

Company raises outlook for Q2 and full-year

BENTONVILLE, Ark–(BUSINESS WIRE)–
Walmart Inc. (NYSE: WMT):

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210518005590/en/

First-quarter highlights:

  • Total revenue was $138.3 billion, an increase of $3.7 billion, or 2.7%. Revenue was negatively affected by approximately $4.2 billion related to recent divestitures in Walmart International. Excluding currency, total revenue would have increased 2.1% to reach $137.4 billion.
  • Walmart U.S. comp sales increased 6.0% with market share gains in grocery. Operating income increased 26.8%.
  • Walmart U.S. eCommerce sales grew 37% with strong results across all channels, contributing approximately 360 basis points to comp sales. Sales more than doubled over the last two years.
  • Sam’s Club comp sales increased 7.2%, and eCommerce sales grew 47%. Reduced tobacco sales negatively affected comp sales by approximately 340 basis points. Membership income increased 12.7%, and total member count reached an all-time high.
  • Walmart International net sales were $27.3 billion, a decrease of $2.5 billion, or 8.3%, and eCommerce sales increased 49%. Net sales were negatively affected by $4.2 billion, or 14.1%, related to recent divestitures, and changes in currency exchange rates positively affected net sales by approximately $0.9 billion.
  • Consolidated gross profit rate increased 104 basis points, led by strength in Walmart U.S., while consolidated operating expenses as a percentage of net sales was relatively flat.
  • Consolidated operating income was $6.9 billion, an increase of 32.3%, with strength across the company. Recently divested businesses in the U.K. and Japan contributed operating income of $289 million, or $0.07 of EPS.
  • Adjusted EPS excludes the effects, net of tax, of:

    • net losses on equity investments of $0.57; and
    • an incremental loss on the sale of our operations in the U.K. and Japan of $0.15

The company will hold a live conference call with the Investment Community at 7 a.m. CDT on Tuesday, May 18, 2021, to discuss the company’s first quarter earnings results for fiscal year 2022. The event will be webcast live and accessible by logging onto https://corporate.walmart.com/newsroom/financial-events and selecting the First Quarter Earnings Release event.

About Walmart

Walmart Inc. (NYSE: WMT) helps people around the world save money and live better – anytime and anywhere – in retail stores, online, and through their mobile devices. Each week, approximately 220 million customers and members visit approximately 10,500 stores and clubs under 48 banners in 24 countries and eCommerce websites. With fiscal year 2021 revenue of $559 billion, Walmart employs over 2.2 million associates worldwide. Walmart continues to be a leader in sustainability, corporate philanthropy and employment opportunity. Additional information about Walmart can be found by visiting corporate.walmart.com, on Facebook at facebook.com/walmart and on Twitter at twitter.com/walmart.

Investor Relations Contacts

Dan Binder, CFA

Vice President, Investor Relations

479-277-0485

Kary Brunner

Sr. Director II, Investor Relations

479-381-9268

Media Relations Contact

Randy Hargrove

Sr. Director, Global Communications

800-331-0085

KEYWORDS: United States North America Arkansas

INDUSTRY KEYWORDS: Fashion Online Retail Retail Discount/Variety Home Goods Supermarket Food/Beverage

MEDIA:

Logo
Logo

Labcorp to Speak at UBS Global Healthcare Virtual Conference

Labcorp to Speak at UBS Global Healthcare Virtual Conference

BURLINGTON, N.C.–(BUSINESS WIRE)–
Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a virtual fireside chat at the UBS Global Healthcare Virtual Conference on Monday, May 24 at 3:00 p.m. ET.

A live webcast of the presentation will be available via the Investor Relations section of the company’s website at www.Labcorp.com and archived for replay.

About Labcorp

Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With more than 70,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $14.0 billion in FY2020. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.

Labcorp Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, including but not limited to statements with respect to the impact of various factors on operating and financial results and the opportunities for future growth.

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the Company’s control, including without limitation, the impact of the COVID-19 pandemic on our business and financial condition as well as on general economic, business, and market conditions, competitive actions and other unforeseen changes and general uncertainties in the marketplace, changes in government regulations, including healthcare reform, customer purchasing decisions, including changes in payer regulations or policies, other adverse actions of governmental and third-party payers, the Company’s satisfaction of regulatory and other requirements, patient safety issues, changes in testing guidelines or recommendations, federal, state, and local governmental responses to the COVID-19 pandemic, adverse results in material litigation matters, failure to maintain or develop customer relationships, our ability to develop or acquire new products and adapt to technological changes, failure in information technology, systems or data security, changes in business conditions and the economy in general, adverse weather conditions, the number of revenue days in a financial period, employee relations, personnel costs, and effect of exchange rate fluctuations. These factors, in some cases, have affected and in the future (together with other factors) could affect the Company’s ability to implement the Company’s business strategy and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

The Company has no obligation to provide any updates to these forward-looking statements even if our expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the Company’s most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the Company’s other filings with the SEC.

# # #

Labcorp Contacts:

Investors: Chas Cook — 336-436-5076

[email protected]

Media: Christopher Allman-Bradshaw — 336-436-8263

[email protected]

 

KEYWORDS: North Carolina United States North America

INDUSTRY KEYWORDS: Research Hospitals Clinical Trials Other Health Health Pharmaceutical General Health Other Science Science

MEDIA:

Logo
Logo

Bristol Myers Squibb to Take Part in UBS Global Healthcare Virtual Conference

Bristol Myers Squibb to Take Part in UBS Global Healthcare Virtual Conference

NEW YORK–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in a fireside chat at the UBS Global Healthcare Virtual Conference, which will be webcast on Tuesday, May 25, 2021. David Elkins, Executive Vice President, Chief Financial Officer and Samit Hirawat, M.D., Executive Vice President, Chief Medical Officer, Global Drug Development, will answer questions about the company at 1 p.m. ET.

Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. An archived edition of the session will be available later that day.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

CorporateFinancial-News

Bristol Myers Squibb

Media:

[email protected]

Investor Relations:

Tim Power, 609-252-7509, [email protected]

Nina Goworek, 908-673-9711, [email protected]

KEYWORDS: United States North America New Jersey

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Oncology General Health Health Infectious Diseases Genetics Other Health

MEDIA:

Logo
Logo

Macy’s, Inc. Reports First Quarter 2021 Results

Macy’s, Inc. Reports First Quarter 2021 Results

Performance exceeded expectations on both the top and bottom lines

Comparable sales up 62.5% vs. 2020 on an owned basis; up 63.9% vs. 2020 on an owned plus licensed basis

Diluted EPS of $0.32 and Adjusted diluted EPS of $0.39

Company continues momentum as a digitally led omnichannel retailer with digital sales growth of 34% vs. 2020

Raises full-year guidance, bolstered by improved macroeconomic trends and strength of Polaris strategy execution

NEW YORK–(BUSINESS WIRE)–
Macy’s, Inc. (NYSE: M) today reported results for the first quarter of 2021 and raised guidance for fiscal 2021.

“In our first quarter we outperformed sales expectations across all three of our brands: Macy’s, Bloomingdale’s and Bluemercury. We built on our momentum from the fourth quarter and our sales trend continued to improve throughout the first quarter,” said Jeff Gennette, chairman and chief executive officer of Macy’s, Inc. “These results were driven by the positive effects of the government stimulus program and expanding vaccine rollout, coupled with the accelerated execution of our Polaris strategy, including investments in our digital platforms. Macy’s remains a fashion and style source for customers as a digitally led omnichannel retailer.”

“As consumers seek to re-engage with each other, we are seeing promising signs that our core customers are shopping again, and we continue to attract new customers, who increasingly begin their shopping experience with us online,” continued Gennette. “Customers are shopping categories that have been strong throughout the pandemic, including home, fine jewelry and watches, fragrance and luxury items. And we’re encouraged by the improvement we’re seeing in special occasion categories as customers begin to travel and return to a pre-pandemic lifestyle. We also have emerging opportunities in new categories and brands, including toys, health & wellness, pet and home décor.”

“As we look to the rest of the year, we are hyper-focused on meeting consumers’ demand for speed, convenience and a seamless omnichannel shopping experience. We also continue to evolve our merchandising strategy, and we remain a partner of choice for top brands with more collaborative and profitable vendor relationships,” continued Gennette. “With a healthier economy and the reopening of communities as the backdrop to the execution of our Polaris strategy, we are well positioned to deliver sustainable, profitable growth in 2021 and the years beyond.”

First Quarter Highlights

In addition to prior year comparisons, Macy’s, Inc. is providing comparisons to 2019 to benchmark its performance given the impact of the pandemic last year.

  • Diluted earnings per share of $0.32 and Adjusted diluted earnings per share of $0.39 both exceeded expectations for the quarter.

    • This compares to $0.44 of both diluted earnings per share and Adjusted diluted earnings per share in first quarter 2019.
    • Excluding asset sale gains, Adjusted diluted earnings per share for the quarter exceeded first quarter 2019 by $0.04.
  • Comparable sales up 62.5% on an owned basis and up 63.9% on an owned plus licensed basis versus 2020.

    • Comparable sales down 10.5% on an owned basis and down 10.0% on an owned plus licensed basis versus 2019.
    • Trend improvement compared to a 17.1% owned plus licensed comparable sales decline in the fourth quarter of 2020.
  • Digital sales grew 34% over first quarter 2020 and grew 32% over first quarter 2019.

    • Digital penetration was 37% of net sales, a 6-percentage point decline from first quarter 2020 when stores closed, but a 13-percentage point improvement over first quarter 2019.
  • The company saw Platinum, Gold and Silver customers in its Star Rewards Loyalty program re-engage, with the average customer spend up 10% compared to first quarter 2019 and an 11-percentage point trend improvement from fourth quarter 2020.

    • The company’s Bronze segment, its youngest and most diverse loyalty tier continued to grow, adding 1.7 million members.

  • The company brought 4.6 million new customers into the Macy’s brand, a 23% increase compared to first quarter 2019.

    • 47% of new customers came through the digital channel in first quarter 2021.

  • Gross margin for the quarter was 38.6%, up from 17.1% in first quarter 2020 and up 40 basis points from first quarter 2019.

    • Improvement due to increased merchandise margin was largely driven by inventory productivity and the execution of the Polaris strategy.
    • The first quarter 2020 included an approximately $300 million inventory write-down from markdowns on fashion merchandise due to the store closures during first quarter 2020.
    • Delivery expense declined approximately 20 basis points from the first quarter of 2020 and increased 230 basis points from first quarter 2019, partially due to the higher penetration of digital sales.

  • Inventory was down 23.1% from first quarter 2019.

    • Continued strong inventory management discipline from 2020.

  • Selling, general and administrative (“SG&A”) expense of $1.7 billion; increased $150 million from first quarter 2020 and declined $364 million from first quarter 2019.

    • SG&A as a percent of sales was 37.1%, down from 52.9% in first quarter of 2020 and an improvement of 130 basis points from first quarter 2019.
    • Disciplined expense management, Polaris savings and improved productivity contributed to the first quarter SG&A performance.
  • Net credit card revenue of $159 million, up $28 million from first quarter 2020 and down $13 million from first quarter 2019.

    • Represented 3.4% of sales, 90 basis points lower than first quarter 2020 and 30 basis points better than first quarter 2019.

  • Approximately $1.8 billion in cash as of the end of the first quarter due to strong performance and the more efficient use of capital compared to pre-pandemic.

Revised FY 2021 Guidance

As a result of Macy’s, Inc. outperformance in the first quarter of 2021 and its improved outlook, the company is raising its full year 2021 guidance.

“Our achievements in the first quarter, combined with the faster than anticipated economic recovery, give us the confidence to update our full-year 2021 guidance,” said Adrian Mitchell, chief financial officer of Macy’s, Inc. “The momentum and strength of our digital business is reshaping how we engage with customers as an omnichannel retailer. As we execute the Polaris strategy, Macy’s, Inc. is well-positioned for long-term, profitable growth.”

 

Revised Guidance 2021

Prior Guidance 2021

Net sales

$21.73B – $22.23B

$19.75B – $20.75B

Adjusted diluted earnings per share

$1.71 – $2.12

$0.40 – $0.90

Adjusted EBITDA as a percent of sales

9% – 9.5%

7% – 7.5%

A full overview of the company’s guidance can be found in the first quarter 2021 earnings presentation at www.macysinc.com/investors.

Conference Call and Webcasts

A webcast of Macy’s, Inc.’s call with analysts and investors to report its first quarter 2021 sales and earnings will be held today (May 18, 2021) at 8:00 a.m. ET. Macy’s, Inc.’s webcast, along with the associated presentation, is accessible to the media and general public via the company’s website at www.macysinc.com/investors. Analysts and investors may call in on 1-800-458-4121, passcode 2736880. A replay of the conference call and slides can be accessed on the website or by calling 1-888-203-1112 (same passcode) about two hours after the conclusion of the call. Additional information on Macy’s, Inc., including past news releases, is available at www.macysinc.com/pressroom.

As previously announced, Adrian Mitchell will present at Cowen’s 2nd Annual New Retail Ecosystem CEO Summit: Innovation & Digitization at 8:15 a.m. ET on May 26, 2021. Media and investors may access a live audio webcast of the presentation at www.macysinc.com. A replay of the webcast will also be available on the company’s website.

Important Information Regarding Financial Measures

Please see the final pages of this news release for important information regarding the calculation of the company’s non-GAAP financial measures.

About Macy’s, Inc.

Macy’s, Inc. (NYSE: M) is one of the nation’s premier omnichannel retailers. Headquartered in New York City, the company comprises three retail brands: Macy’s, Bloomingdale’s and Bluemercury. With a robust e-commerce business, rich mobile experience and a national stores footprint, our customers can shop the way they live — anytime and through any channel. For more information, visit macysinc.com.

Forward-Looking Statements

All statements in this press release that are not statements of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon the current beliefs and expectations of Macy’s management and are subject to significant risks and uncertainties. Actual results could differ materially from those expressed in or implied by the forward-looking statements contained in this release because of a variety of factors, including the effects of the COVID-19 pandemic on Macy’s customer demand and supply chain, as well as its consolidated results of operation, financial position and cash flows, Macy’s ability to successfully implement its Polaris strategy, including the ability to realize the anticipated benefits within the expected time frame or at all, conditions to, or changes in the timing of proposed real estate and other transactions, prevailing interest rates and non-recurring charges, the effect of potential changes to trade policies, store closings, competitive pressures from specialty stores, general merchandise stores, off-price and discount stores, manufacturers’ outlets, the Internet and catalogs and general consumer spending levels, including the impact of the availability and level of consumer debt, possible systems failures and/or security breaches, the potential for the incurrence of charges in connection with the impairment of intangible assets, including goodwill, Macy’s reliance on foreign sources of production, including risks related to the disruption of imports by labor disputes, regional or global health pandemics, and regional political and economic conditions, the effect of weather and other factors identified in documents filed by the company with the Securities and Exchange Commission, including under the captions “Forward-Looking Statements” and “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended January 30, 2021. Macy’s disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

MACY’S, INC.

Consolidated Statements of Operations (Unaudited) (Note 1)

(All amounts in millions except percentages and per share figures)

 

 

 

13 Weeks Ended

May 1, 2021

 

 

13 Weeks Ended

May 2, 2020

 

 

 

 

 

 

 

% to

 

 

 

 

 

 

% to

 

 

 

$

 

 

Net sales

 

 

$

 

 

Net sales

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

$

4,706

 

 

 

 

 

 

$

3,017

 

 

 

 

 

Credit card revenues, net

 

 

159

 

 

 

3.4

%

 

 

131

 

 

 

4.3

%

Cost of sales

 

 

(2,889

)

 

 

(61.4

%)

 

 

(2,501

)

 

 

(82.9

%)

Selling, general and administrative expenses

 

 

(1,748

)

 

 

(37.1

%)

 

 

(1,598

)

 

 

(52.9

%)

Gains on sale of real estate

 

 

6

 

 

 

0.1

%

 

 

16

 

 

 

0.5

%

Impairment, restructuring and other costs (Note 2)

 

 

(19

)

 

 

(0.4

%)

 

 

(3,184

)

 

 

(105.5

%)

Operating income (loss)

 

 

215

 

 

 

4.6

%

 

 

(4,119

)

 

 

(136.5

%)

Benefit plan income, net

 

 

15

 

 

 

 

 

 

 

9

 

 

 

 

 

Interest expense, net

 

 

(79

)

 

 

 

 

 

 

(47

)

 

 

 

 

Losses on early retirement of debt

 

 

(11

)

 

 

 

 

 

 

 

 

 

 

 

Income (loss) before income taxes

 

 

140

 

 

 

 

 

 

 

(4,157

)

 

 

 

 

Federal, state and local income tax benefit (expense) (Note 3)

 

 

(37

)

 

 

 

 

 

 

576

 

 

 

 

 

Net income (loss)

 

$

103

 

 

 

 

 

 

$

(3,581

)

 

 

 

 

Basic earnings (loss) per share

 

$

0.33

 

 

 

 

 

 

$

(11.53

)

 

 

 

 

Diluted earnings (loss) per share

 

$

0.32

 

 

 

 

 

 

$

(11.53

)

 

 

 

 

Average common shares:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

311.6

 

 

 

 

 

 

 

310.6

 

 

 

 

 

Diluted

 

 

318.6

 

 

 

 

 

 

 

310.6

 

 

 

 

 

End of period common shares outstanding

 

 

311.0

 

 

 

 

 

 

 

310.2

 

 

 

 

 

Supplemental Financial Measures:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross Margin (Note 4)

 

$

1,817

 

 

 

38.6

%

 

$

516

 

 

 

17.1

%

Depreciation and amortization expense

 

$

224

 

 

 

 

 

 

$

237

 

 

 

 

 

MACY’S, INC.

Consolidated Balance Sheets (Unaudited) (Note 1)

(millions)

 

 

 

May 1,

2021

 

 

January 30,

2021

 

 

May 2,

2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ASSETS:

 

 

 

 

 

 

 

 

 

 

 

 

Current Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

1,798

 

 

$

1,679

 

 

$

1,523

 

Receivables

 

 

205

 

 

 

276

 

 

 

170

 

Merchandise inventories

 

 

4,230

 

 

 

3,774

 

 

 

4,923

 

Prepaid expenses and other current assets (Note 6)

 

 

1,007

 

 

 

455

 

 

 

519

 

Total Current Assets

 

 

7,240

 

 

 

6,184

 

 

 

7,135

 

Property and Equipment – net

 

 

5,798

 

 

 

5,940

 

 

 

6,425

 

Right of Use Assets

 

 

2,853

 

 

 

2,878

 

 

 

2,672

 

Goodwill

 

 

828

 

 

 

828

 

 

 

838

 

Other Intangible Assets – net

 

 

436

 

 

 

437

 

 

 

439

 

Other Assets

 

 

926

 

 

 

1,439

 

 

 

1,072

 

Total Assets

 

$

18,082

 

 

$

17,706

 

 

$

18,581

 

LIABILITIES AND SHAREHOLDERS’ EQUITY:

 

 

 

 

 

 

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Short-term debt

 

$

294

 

 

$

452

 

 

$

739

 

Merchandise accounts payable

 

 

2,545

 

 

 

1,978

 

 

 

2,196

 

Accounts payable and accrued liabilities

 

 

2,616

 

 

 

2,927

 

 

 

2,757

 

Income taxes

 

 

63

 

 

 

 

 

 

80

 

Total Current Liabilities

 

 

5,518

 

 

 

5,357

 

 

 

5,772

 

Long-Term Debt

 

 

4,558

 

 

 

4,407

 

 

 

4,918

 

Long-Term Lease Liabilities

 

 

3,166

 

 

 

3,185

 

 

 

2,923

 

Deferred Income Taxes

 

 

868

 

 

 

908

 

 

 

944

 

Other Liabilities

 

 

1,296

 

 

 

1,296

 

 

 

1,327

 

Shareholders’ Equity

 

 

2,675

 

 

 

2,553

 

 

 

2,697

 

Total Liabilities and Shareholders’ Equity

 

$

18,082

 

 

$

17,706

 

 

$

18,581

 

MACY’S, INC.

Consolidated Statements of Cash Flows (Unaudited) (Notes 1 and 5)

(millions)

 

 

 

13 Weeks Ended

May 1, 2021

 

 

13 Weeks Ended

May 2, 2020

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net income (loss)

 

$

103

 

 

$

(3,581

)

Adjustments to reconcile net income (loss) to net cash provided (used) by operating activities:

 

 

 

 

 

 

 

 

Impairment, restructuring and other costs

 

 

19

 

 

 

3,184

 

Depreciation and amortization

 

 

224

 

 

 

237

 

Benefit plans

 

 

10

 

 

 

12

 

Stock-based compensation expense

 

 

11

 

 

 

6

 

Gains on sale of real estate

 

 

(6

)

 

 

(16

)

Deferred income taxes

 

 

(43

)

 

 

(225

)

Amortization of financing costs and premium on acquired debt

 

 

8

 

 

 

 

Changes in assets and liabilities:

 

 

 

 

 

 

 

 

Decrease in receivables

 

 

71

 

 

 

236

 

(Increase) decrease in merchandise inventories

 

 

(457

)

 

 

265

 

(Increase) decrease in prepaid expenses and other current assets

 

 

(56

)

 

 

12

 

Increase in merchandise accounts payable

 

 

674

 

 

 

629

 

Decrease in accounts payable and accrued liabilities

 

 

(114

)

 

 

(531

)

(Increase) decrease in current income taxes

 

 

75

 

 

 

(353

)

Change in other assets and liabilities

 

 

(25

)

 

 

(39

)

Net cash provided (used) by operating activities

 

 

494

 

 

 

(164

)

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Purchase of property and equipment

 

 

(61

)

 

 

(122

)

Capitalized software

 

 

(38

)

 

 

(38

)

Disposition of property and equipment

 

 

8

 

 

 

21

 

Other, net

 

 

17

 

 

 

26

 

Net cash used by investing activities

 

 

(74

)

 

 

(113

)

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Debt issued

 

 

500

 

 

 

1,500

 

Debt issuance costs

 

 

(9

)

 

 

 

Debt repaid

 

 

(503

)

 

 

(4

)

Debt repurchase premium and expenses

 

 

(12

)

 

 

 

 

Dividends paid

 

 

 

 

 

(117

)

Decrease in outstanding checks

 

 

(276

)

 

 

(231

)

Net cash provided (used) by financing activities

 

 

(300

)

 

 

1,148

 

Net increase in cash, cash equivalents and restricted cash

 

 

120

 

 

 

871

 

Cash, cash equivalents and restricted cash beginning of period

 

 

1,754

 

 

 

731

 

Cash, cash equivalents and restricted cash end of period

 

$

1,874

 

 

$

1,602

 

MACY’S, INC.

Consolidated Financial Statements (Unaudited)

 

Notes:

 

(1)

As a result of the seasonal nature of the retail business, the results of operations for the 13 weeks ended May 1, 2021 and May 2, 2020 (which do not include the Christmas season) are not necessarily indicative of such results for the fiscal year.

 

(2)

The 13 weeks ended May 2, 2020 included non-cash impairment charges totaling $3.2 billion, which consisted of $3.1 billion of a non-cash goodwill impairment charge and $80 million impairment charge on long-lived tangible and right of use assets.

 

(3)

The income tax expense of $37 million and the income tax benefit of $576 million, or 26.3% and 13.9% of pretax income and loss, for the 13 weeks ended May 1, 2021 and May 2, 2020, respectively, reflect a different effective tax rate as compared to the company’s federal income tax statutory rate of 21%. The income tax effective rate for the 13 weeks ended May 1, 2021 was impacted by the realization of deferred tax assets associated with the vesting and cancellation of certain stock-based compensation awards. The income tax effective rate for the 13 weeks ended May 2, 2020 was impacted by the non-tax deductible component of the goodwill impairment charge, offset partially by the benefit of the available carryback of net operating losses as permitted under the CARES Act.

 

(4)

Gross margin is defined as net sales less cost of sales.

 

(5)

Restricted cash of $76 million and $79 million have been included with cash and cash equivalents for the 13 weeks ended May 1, 2021 and May 2, 2020, respectively.

 

(6)

Prepaid expenses and other current assets as of May 2, 2021 include an income tax receivable of $520 million.

MACY’S, INC.

Important Information Regarding Non-GAAP Financial Measures

 

The company reports its financial results in accordance with U.S. generally accepted accounting principles (GAAP). However, management believes that certain non-GAAP financial measures provide users of the company’s financial information with additional useful information in evaluating operating performance. Management believes that providing supplemental changes in comparable sales on an owned plus licensed basis, which includes adjusting for the impact of comparable sales of departments licensed to third parties, assists in evaluating the company’s ability to generate sales growth, whether through owned businesses or departments licensed to third parties, and in evaluating the impact of changes in the manner in which certain departments are operated. Earnings (loss) before interest, taxes, depreciation and amortization (EBITDA) is a non-GAAP financial measure which the company believes provides meaningful information about its operational efficiency by excluding the impact of changes in tax law and structure, debt levels and capital investment. In addition, management believes that excluding certain items from EBITDA, net income (loss) and diluted earnings (loss) per share that are not associated with the company’s core operations and that may vary substantially in frequency and magnitude from period-to-period provides useful supplemental measures that assist in evaluating the company’s ability to generate earnings and to more readily compare these metrics between past and future periods.

 

The company does not provide reconciliations of the forward-looking non-GAAP measures of adjusted EBITDA and diluted earnings per share to the most directly comparable forward-looking GAAP measures because the timing and amount of excluded items are unreasonably difficult to fully and accurately estimate. For the same reasons, the company is unable to address the probable significance of the unavailable information, which could be material to future results.

 

Non-GAAP financial measures should be viewed as supplementing, and not as an alternative or substitute for, the company’s financial results prepared in accordance with GAAP. Certain of the items that may be excluded or included in non-GAAP financial measures may be significant items that could impact the company’s financial position, results of operations or cash flows and should therefore be considered in assessing the company’s actual and future financial condition and performance. Additionally, the amounts received by the company on account of sales of departments licensed to third parties are limited to commissions received on such sales. The methods used by the company to calculate its non-GAAP financial measures may differ significantly from methods used by other companies to compute similar measures. As a result, any non-GAAP financial measures presented herein may not be comparable to similar measures provided by other companies.

MACY’S, INC.

Important Information Regarding Non-GAAP Financial Measures

(All amounts in millions except percentages and per share figures)

 

Changes in Comparable Sales

 

 

 

Comparable Sales

vs.

13 Weeks Ended

May 2, 2020

 

 

Comparable Sales

vs.

13 Weeks Ended

May 4, 2019

 

 

 

 

 

 

 

 

 

 

Increase (decrease) in comparable sales on an owned basis (Note 7)

 

 

62.5

%

 

 

(10.5

%)

 

 

 

 

 

 

 

 

 

Comparable sales impact of departments licensed to third parties (Note 8)

 

 

1.4

%

 

 

0.5

%

 

 

 

 

 

 

 

 

 

Increase (decrease) in comparable sales on an owned plus licensed basis

 

 

63.9

%

 

 

(10.0

%)

Notes:

 

(7)

Represents the period-to-period percentage change in net sales from stores in operation during the 13 weeks ended May 1, 2021 and the 13 weeks ended May 2, 2020 and May 4, 2019, respectively. Such calculation includes all digital sales and excludes commissions from departments licensed to third parties. Stores impacted by a natural disaster or undergoing significant expansion or shrinkage remain in the comparable sales calculation unless the store, or material portion of the store, is closed for a significant period of time. No stores have been excluded as a result of the COVID-19 pandemic. Definitions and calculations of comparable sales may differ among companies in the retail industry.

 

(8)

Represents the impact of including the sales of departments licensed to third parties occurring in stores in operation throughout the year presented and the immediately preceding year and all online sales in the calculation of comparable sales. The company licenses third parties to operate certain departments in its stores and online and receives commissions from these third parties based on a percentage of their net sales. In its financial statements prepared in conformity with GAAP, the company includes these commissions (rather than sales of the departments licensed to third parties) in its net sales. The company does not, however, include any amounts in respect of licensed department sales (or any commissions earned on such sales) in its comparable sales in accordance with GAAP (i.e., on an owned basis). The amounts of commissions earned on sales of departments licensed to third parties are not material to its net sales for the periods presented.

MACY’S, INC.

Important Information Regarding Non-GAAP Financial Measures

(All amounts in millions except percentages and per share figures)

 

Earnings (Loss) before Interest, Taxes, Depreciation and Amortization, Net Income (Loss) and Diluted Earnings (Loss) Per Share, Excluding Certain Items

Non-GAAP financial measures, excluding certain items below, are reconciled to the most directly comparable GAAP measure as follows:

  • EBITDA and adjusted EBITDA are reconciled to GAAP net income (loss).
  • Adjusted net income (loss) is reconciled to GAAP net income (loss).
  • Adjusted diluted earnings (loss) per share is reconciled to GAAP diluted earnings (loss) per share.
 

EBITDA and Adjusted EBITDA

 

 

 

13 Weeks Ended

May 1, 2021

 

 

13 Weeks Ended

May 2, 2020

 

 

13 Weeks Ended

May 4, 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

 

$

103

 

 

$

(3,581

)

 

$

136

 

Interest expense, net

 

 

79

 

 

 

47

 

 

 

47

 

Losses on early retirement of debt

 

 

11

 

 

 

 

 

 

 

Federal, state and local income tax expense (benefit)

 

 

37

 

 

 

(576

)

 

 

27

 

Depreciation and amortization

 

 

224

 

 

 

237

 

 

 

236

 

EBITDA

 

 

454

 

 

 

(3,873

)

 

 

446

 

Impairment, restructuring and other costs

 

 

19

 

 

 

3,184

 

 

 

1

 

Adjusted EBITDA

 

$

473

 

 

$

(689

)

 

$

447

 

MACY’S, INC.

Important Information Regarding Non-GAAP Financial Measures

(All amounts in millions except percentages and per share figures)

 

Adjusted Net Income (Loss) and Adjusted Diluted Earnings (Loss) Per Share

 

 

 

13 Weeks Ended

May 1, 2021

 

 

13 Weeks Ended

May 2, 2020

 

 

13 Weeks Ended

May 4, 2019

 

 

 

Net

Income

 

 

Diluted

Earnings

Per Share

 

 

Net

Income

(Loss)

 

 

Diluted

Earnings

(Loss)

Per Share

 

 

Net

Income

 

 

Diluted

Earnings

Per Share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

As reported

 

$

103

 

 

$

0.32

 

 

$

(3,581

)

 

$

(11.53

)

 

$

136

 

 

$

0.44

 

Impairment, restructuring and other costs

 

 

19

 

 

 

0.06

 

 

 

3,184

 

 

 

10.25

 

 

 

1

 

 

 

 

Losses on early retirement of debt

 

 

11

 

 

 

0.03

 

 

 

 

 

 

 

 

 

 

 

 

 

Income tax impact of certain items identified above

 

 

(7

)

 

 

(0.02

)

 

 

(233

)

 

 

(0.75

)

 

 

 

 

 

 

As adjusted to exclude certain items above

 

$

126

 

 

$

0.39

 

 

$

(630

)

 

$

(2.03

)

 

$

137

 

 

$

0.44

 

Gains on sale of real estate

 

 

(6

)

 

 

(0.02

)

 

 

(16

)

 

 

(0.05

)

 

 

(43

)

 

 

(0.14

)

Income tax impact of gains on sale of real estate

 

 

1

 

 

 

0.01

 

 

 

4

 

 

 

0.01

 

 

 

12

 

 

 

0.04

 

As adjusted to exclude gains on sale of real estate and other certain items identified above

 

$

121

 

 

$

0.38

 

 

$

(642

)

 

$

(2.07

)

 

$

106

 

 

$

0.34

 

 

Media – Blair Rosenberg

[email protected]

Investors – Mike McGuire

[email protected]

KEYWORDS: New York Ohio United States North America

INDUSTRY KEYWORDS: Home Goods Retail Other Consumer Women Online Retail Luxury Teens Catalog Other Retail Men Department Stores Children Specialty Family Consumer Fashion

MEDIA:

Logo
Logo

Ryder CEO to Address Wolfe Research Transportation and Industrials Conference

Ryder CEO to Address Wolfe Research Transportation and Industrials Conference

MIAMI–(BUSINESS WIRE)–
Ryder System, Inc. (NYSE: R) Chairman and Chief Executive Officer Robert Sanchez will present a company update at the Wolfe Research Transportation and Industrials Conference.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210518005024/en/

Ryder System, Inc. Chairman and Chief Executive Officer Robert Sanchez (Photo: Business Wire)

Ryder System, Inc. Chairman and Chief Executive Officer Robert Sanchez (Photo: Business Wire)

Who:

Ryder System, Inc. Chairman and Chief Executive Officer Robert Sanchez

 

What:

Wolfe Research Transportation and Industrials Conference

 

Where:

Virtual Event

 

When:

Tuesday, May 25, 2021

 

Time:

2:25 p.m. Eastern Standard Time

 

Webcast:

To access the live webcast, visit http://investors.ryder.com.

 

About Ryder

Ryder System, Inc. (NYSE: R) is a leading logistics and transportation company. It provides supply chain, dedicated transportation, and fleet management solutions, including full service leasing, rental, and maintenance, used vehicle sales, professional drivers, transportation services, freight brokerage, warehousing and distribution, e-commerce fulfillment, and last mile delivery services, to some world’s most-recognized brands. Ryder provides services throughout the United States, Mexico, Canada, and the United Kingdom. In addition, Ryder manages nearly 235,000 commercial vehicles and operates more than 300 warehouses encompassing approximately 64 million square feet. Ryder is regularly recognized for its industry-leading practices in third-party logistics, technology-driven innovations, commercial vehicle maintenance, environmentally friendly solutions, corporate social responsibility, world-class safety and security programs, military veteran recruitment initiatives, and the hiring of a diverse workforce. www.ryder.com

Note Regarding Forward-Looking Statements: Certain statements and information included in this news release are “forward-looking statements” within the meaning of the Federal Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on our current plans and expectations and are subject to risks, uncertainties and assumptions. Accordingly, these forward-looking statements should be evaluated with consideration given to the many risks and uncertainties that could cause actual results and events to differ materially from those in the forward-looking statements including those risks set forth in our periodic filings with the Securities and Exchange Commission. New risks emerge from time to time. It is not possible for management to predict all such risk factors or to assess the impact of such risks on our business. Accordingly, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

ryder-financial

ryder-usa

Amy Federman

(305) 500-4989

[email protected]

Bob Brunn

(305) 500-4053

[email protected]

KEYWORDS: Florida United States North America

INDUSTRY KEYWORDS: Other Transport Trucking Rail Automotive Transport Automotive Manufacturing Manufacturing Logistics/Supply Chain Management Fleet Management

MEDIA:

Photo
Photo
Ryder System, Inc. Chairman and Chief Executive Officer Robert Sanchez (Photo: Business Wire)